Synthaverse lands $11.6M state loan to refinance debt before 2027 plant launch
What's the deal? Polish pharmaceutical company Synthaverse has secured a US$11.3M (≈$11.6 million) loan from Poland's Industrial Development Agency. The post-IPO debt facility, confirmed on October 16, 2026, is designed to replace debt owed to ACPDealroom has a profile for this one. Try Dealroom → and reshape the company's funding structure.
Why now? The refinancing arrives ahead of commercial production at Synthaverse's new Onko BCG plant, currently targeted for late 2027. It eases balance-sheet pressure before that ramp-up: the loan runs up to 120 months, with a principal repayment grace period of up to 24 months.
What does it change? Management estimates the completed refinancing could cut annual financial costs by about US$1.33M. Interest is set at WIBOR 1M plus a margin of 3.5 to 4.0 percentage points, with a possible reduction to 2.5 points once net debt to EBITDA falls below 3.0.
The numbers: First-half 2026 revenue rose 34% to US$6.62M, up from US$4.93M a year earlier, while EBITDA more than doubled to US$1.35M. But the company still posted a net loss of US$1.59M, wider than the US$1.33M loss a year earlier, as financing costs kept the bottom line negative.
What could go wrong? This is refinancing, not fresh growth capital — and completion remains conditional. Synthaverse still needs documentation, creditor agreements, security arrangements, and a planned equity issue plus US$2.63M to US$2.88M in additional bank financing. Reported net debt stood at about US$20.8M at the end of June.
Synthaverse stock was last quoted at US$0.7 on October 16, 2026, valuing the company at US$53.4M. Its next earnings report is scheduled for December 2, 2026.
The signal: State-backed debt is buying a listed biotech time. With revenue climbing and a new plant on the horizon but losses persisting, the loan is a liquidity milestone rather than a fix — the share issue and final refinancing still have to land.
Read more: ad-hoc-news.de
Image credit: Generated with Gemini
